Literature DB >> 22996074

Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.

Anne Charlotte Danton1, François Montastruc, Agnès Sommet, Geneviève Durrieu, Haleh Bagheri, Emmanuelle Bondon-Guitton, Maryse Lapeyre-Mestre, Jean-Louis Montastruc.   

Abstract

OBJECTIVE: Our aim was to characterize Adverse Drug Reactions (ADRs) related to drug-drug interactions (DDIs) related to involvement of cytochrome P450 (CYP450) isoenzymes in a pharmacovigilance database.
METHODS: ADRs recorded by Midi-Pyrénées PharmacoVigilance center (France) between 1 January and 31 August 2008 were extracted from the French PharmacoVigilance Database (FPVD).
RESULTS: Among the 1,205 reported ADRs, 16 (1.3 %), can be explained by involvement of CYP450 isoenzymes (including 4 "serious"). All interactions involved CYP inhibitors, mainly for CYP3A4/5.
CONCLUSION: The percentage of ADRs reported in the pharmacovigilance database and related to CYP450-induced DDIs appears to be relatively low (~ 1-2 %).

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22996074     DOI： 10.1007/s00228-012-1394-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  The medical dictionary for regulatory activities (MedDRA).

Authors:  E G Brown; L Wood; S Wood
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

2.  [Drug interactions: a prospective pilot study in primary health care].

Authors:  N Rémy; M Lapeyre-Mestre; M P Bareille; H Bagheri; J L Montastruc
Journal:  Therapie       Date:  2000 May-Jun       Impact factor: 2.070

3.  Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.

Authors:  Roberto Leone; Lara Magro; Ugo Moretti; Paola Cutroneo; Martina Moschini; Domenico Motola; Marco Tuccori; Anita Conforti
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

4.  Drug-drug interactions: is there an optimal way to study them?

Authors:  L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

5.  Drug interactions should be evaluated in patients.

Authors:  C V Fletcher
Journal:  Clin Pharmacol Ther       Date:  2010-11       Impact factor: 6.875

6.  Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.

Authors:  Tobias Egger; Harald Dormann; Gabi Ahne; Andreas Pahl; Ulrich Runge; Tanya Azaz-Livshits; Antje Neubert; Manfred Criegee-Rieck; Karl G Gassmann; Kay Brune
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

7.  The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.

Authors:  Francois Montastruc; Agnès Sommet; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Eric Bui; Haleh Bagheri; Maryse Lapeyre-Mestre; Laurent Schmitt; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2011-11-25       Impact factor: 2.953

8.  [French pharmacovigilance database system: examples of utilisation].

Authors:  N Moore; C Noblet; C Kreft-Jais; G Lagier; M Ollagnier; J L Imbs
Journal:  Therapie       Date:  1995 Nov-Dec       Impact factor: 2.070

9.  Identification of adverse drug reactions in geriatric inpatients using a computerised drug database.

Authors:  Tobias Egger; Harald Dormann; Gabi Ahne; Ulrich Runge; Antje Neubert; Manfred Criegee-Rieck; Karl G Gassmann; Kay Brune
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Epidemiology of drug-drug interactions as a cause of hospital admissions.

Authors:  C A Jankel; L K Fitterman
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606
View more
  3 in total

1.  Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database.

Authors:  François Montastruc; Sarah Rouanet; Virginie Gardette; Vanessa Rousseau; Haleh Bagheri; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2015-05-21       Impact factor: 2.953

2.  Machine learning workflow to enhance predictions of Adverse Drug Reactions (ADRs) through drug-gene interactions: application to drugs for cutaneous diseases.

Authors:  Kalpana Raja; Matthew Patrick; James T Elder; Lam C Tsoi
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

3.  Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro.

Authors:  Weiping Ji; Jiquan Shen; Bo Wang; Feifei Chen; Deru Meng; Shuanghu Wang; Dapeng Dai; Yunfang Zhou; Changxiong Wang; Quan Zhou
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.